Post Brexit: Small Service Businesses

Debate between Baroness Bull and Lord Callanan

Monday 24th May 2021 Lords Chamber

[Lord Callanan (Con)]

Of course; we are more than interested and keen to ease burdens as much as possible. It requires a willing partner on the EU side to engage in constructive discussions, but we will continue attempting that.

[Baroness Bull (CB)]

My Lords, the increased costs and complexity of post-Brexit touring, about which we have heard, are particularly acute for the many micro-businesses in the cultural sector which do not have access to the resources or specialist skills needed to navigate multiple regimes in EU states. Can the Minister say what further discussion there has been about the establishment of a new creative export office to provide expert advice and support since Ministers first mooted the idea in February? Can he say what the remit of this office would be?

[Lord Callanan (Con)]

The noble Baroness makes some very good points, and I know that she has raised this point about the provision of services before. Regarding the creation of the creative export office, I will speak to my colleagues in DCMS who have responsibility for this and write to her with the details.

EU Coronavirus Vaccine Programme

Debate between Baroness Bull and Lord Callanan

Monday 13th July 2020 Lords Chamber

[Lord Callanan]

Other EU member states would have been able to take part in the governance of the scheme; we would not. Even though the main development is funded from the EU budget, any individual procurement or orders would come from national budgets. Crucially, we would not have been able to negotiate in parallel with other companies with which we already have a good working relationship.

[Baroness Bull (CB) [V]]

My Lords, new research from King’s College London, in which I declare my interest as an employee, suggests that immunity from Covid-19 may last just a few months, indicating that mass, or herd, immunity from the disease is not an effective strategy, that vaccination boosters may be required, and that any cavalier approach to infection on the basis that one might as well get it in order to acquire the protection of immunity is woefully misguided. What assessment have the Government made of the impact of these findings on their vaccination strategy and their approach to vaccine development?

[Lord Callanan]

The Vaccine Taskforce is of course considering all the academic work being done in this field; it is a rapidly developing sphere of science. I am sure that we welcome the work taking place at the institution mentioned by the noble Baroness, but a lot of other research institutes are already looking into it. There are a number of developing vaccine forms which require different manufacturing processes to produce individual vaccines, and we are of course evaluating all of them.